Introduction
Overall survival for ALL in children exceeds 85%. 1 Improved survival primarily stems from decreased incidence of relapse, with very little improvement for more than twenty years in survival rates for children who relapse. [2] [3] [4] In contrast, overall survival for adults with ALL is quite poor (30-40%), 5, 6 and relapsed ALL remains particularly challenging for all age groups, making it a leading cause of cancer deaths in children and carrying a dismal prognosis in adults. 2, 4, 7 Most children in first relapse will achieve a second remission (CR2), in contrast to the adult population, in which CR2 rates are 50% at best. 2, 4, 7 Even for patients who achieve CR2, those remissions are frequently not sustained. 2, 4 With each subsequent relapse, achieving remission is harder and longterm survival is extremely poor. 4 Refractory ALL is also challenging, with long-term survival close to 30%. 8 For those who do not achieve a remission, options are limited.
Several ALL subtypes with high-risk genotypes have been characterized beyond BCR-ABL1-driven Philadelphia Chromosome (Ph)-positive ALL. In the future, genetic lesions may be targeted by inhibitors aimed at intracellular or extracellular molecules expressed by leukemic blasts, as suggested by the use of imatinib 9, 10 . While promising examples exist, [11] [12] [13] the majority of ALL cases do not have a known driver lesion. Thus, the current state of ALL therapy is that these genomic discoveries will first be used to detect patients at higher risk of recurrence, a group of patients for whom novel therapies are needed.
Targeted immunotherapy is another attractive alternative that has emerged as a potent therapy and will be the subject of this review. CAR-modified T cells targeting CD19, the For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From best-studied CAR T cell therapy to date, will be discussed, with a focus on clinical trials for ALL demonstrating efficacy as well as toxicity and toxicity management.
Immunotherapy Rationale
Potentially malignant cells are continuously eliminated by apoptosis and the immune system, but cancers have escaped these mechanisms. For immune-mediated clearance of leukemia to be possible, tolerance has to be overcome. This is the basis for the graftversus-leukemia (GVL) effect, which contributes in part to the efficacy of allogeneic stem cell transplantation (SCT) and is the rationale for donor lymphocyte infusion (DLI) in leukemia. 14 While DLI has been less efficacious in ALL, GVL efficacy in ALL is recognized. A recent Children's Oncology Group trial demonstrated that relapse risk was significantly lower in patients who developed acute graft-versus-host disease (GVHD) after allogeneic SCT for ALL compared to those who did not. 15 However, the GVL effect carries the significant risk of GVHD.
Use of autologous T cells would remove the risk of GVHD, but requires a means of breaking tolerance to self. One method involves reprogramming T cells to identify and eliminate malignant cells through tumor-specific antigen recognition. CARs link an extracellular antigen-recognition domain, derived from a monoclonal antibody fragment (scFv), to intracellular signaling domains of the T cell receptor complex. T cells engineered to express such CARs engage an antigen on a tumor cell through the extracellular antibody domain, thereby activating the T cells in an MHC-independent manner and stimulating a potent cytotoxic response.
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T Cell Engineering and Manufacture
The concept of CARs was first described twenty-five years ago as a means of introducing tumor specificity into adoptive cell therapy. 16 The initial design joined an antibody-derived scFv to the CD3ζ intracellular signaling domain of the T cell receptor through hinge and transmembrane domains. While the first CARs showed evidence of function preclinically and limited responses in clinical trials (reviewed in [17] [18] [19] ), fine-tuning was needed to optimize both in vitro and in vivo T cell proliferation and persistence. As iterative modifications were made, this fundamental design was dubbed a "firstgeneration" CAR. "Second-generation" CARs incorporate an additional domain, CD28 or 4-1BB, to supply a co-stimulatory signal. Two co-stimulatory domains, a combination of CD27, CD28, 4-1BB, ICOS, or OX40, make up "third-generation" CARs. [20] [21] [22] [23] First, second, and third-generation CARs are depicted in Figures 1 and 2 .
CAR designs not only differ in their components but also in their functional properties.
The CD3ζ signaling domain of the T cell receptor, when engaged, will activate and induce proliferation of T cells, but can lead to anergy. The addition of a costimulatory domain in "second-generation" CARs improved replicative capacity and persistence of modified T cells. Which costimulatory domain is optimal is unknown. Similar antitumor effects are seen in vitro with CD28 or 4-1BB CARs, but preclinical in vivo studies 22 suggest that 4-1BB CARs ( Figure 2 ) may produce superior proliferation and/or persistence. 21, 24 Moreover, clinical trials suggest that both of these "second-generation"
CARs are capable of inducing substantial T cell proliferation in vivo, but CARs containing the 4-1BB costimulatory domain appear to persist longer.
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For personal use only. CD19 is a B cell surface protein expressed throughout B cell development; therefore, it is expressed on nearly all B cell malignancies, including chronic lymphocytic leukemia (CLL), ALL, and many non-Hodgkin lymphomas. 39 This near universal expression and specificity for a single cell lineage has made CD19 an attractive target for CAR-modified
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From T cell therapies. Additional B cell-specific cell surface molecules, such as CD22, may hold similar promise and are under active investigation. 40 Target identification for T-cell ALL poses a particular challenge as leukemic blasts express the same antigens as normal T cells; therefore, CAR immunotherapy may not be possible in T-ALL. This is because B cell aplasia is treatable and tolerable, while T cell aplasia is not. While select T-ALL subsets may aberrantly express cell surface proteins that are not normally expressed on T cells or express abnormal fusion proteins, there is no universal target that is specific to T lymphoblasts. 
CD19 CAR Clinical

CLL
We first showed that CD19 directed CAR T cells could induce complete remissions (CR)
for some patients with advanced, heavily pre-treated and high-risk CLL; all 3 of the first patients treated had dramatic anti-tumor responses including 2 patients with long-term 44 We have now treated over 45 patients with advanced relapsed and refractory CLL. Response rates are approximately 45% with remissions in some patients extending beyond 4 years (unpublished data). All patients who respond and have persistent CAR-modified T cells also develop B cell aplasia and hypogammaglobulinemia, perhaps considered "on-target" toxicity but also a measure of functional persistence. The most significant and unique toxicity is CRS, similar to patients with ALL; however, for reasons that are not well-defined, the incidence and severity of CRS appears to be lower in CLL than ALL despite CLL patients having very high tumor burdens.
ALL
The first reports of efficacy in ALL, while hopeful, needed to be expanded to determine the CR rate. With larger studies now published by three groups, using different CD19
CAR designs, the efficacy is even better than expected with CR rates of 70-90%.
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Our group has reported a 90% CR rate in 30 pediatric and adult patients with relapsed/refractory ALL treated on Children's Hospital of Philadelphia (CHOP) and The initial responses are comparable across different studies, institutions, and CAR designs, which is encouraging in terms of the ability to replicate these promising results.
However, persistence of CAR-modified T cells and long-term outcomes can vary and may distinguish CAR designs. In general, CAR T cell persistence appears to be shorter in some patients with ALL compared to CLL patients who respond, even though CR rates are higher in ALL. 49 The kinetics of tumor growth and elimination are markedly different between these two diseases. Combined with the ongoing antigen reservoir provided by bulky disease characteristic of CLL, these factors may account for this difference. However, the persistence of T cells engineered to express a CD19-targeted CAR is also discrepant across ALL studies.
In the MSKCC ALL cohort, Davila et al. report 1-3 month persistence of 19-28z CAR T cells. 25 Similarly, with the NCI's CD19-CAR T cells (CD28 costimulatory domain), the longest persistence reported is 68 days with rapid B cell recovery seen. 27 In our ALL cohort treated with CTL019 T cells (4-1BB costimulatory domain), many patients had longer persistence (up to 2 years) with the probability of CTL019 persistence at 6 months being 68% (95% CI: 50-92%). 26 The duration of B cell aplasia, also longer at up to 2 years, suggests continued effector function of CTL019 cells.
Durable remissions have also been reported across studies, but were only described in the approximately 50% of patients proceeding to allogeneic SCT in the NCI and MSKCC cohorts. In the CHOP/Penn cohort, sustained remissions of 2-24 months were 1 1 seen in 19/27 responding patients, 15 of whom received no further therapy. 26 Event-free survival at 6 months was 67% (95% CI: 51-88%; Figure 3 ) and overall survival at 6 months was 78% (95% CI: 65-95%). Updates from 39 pediatric patients with ALL were presented at ASH 2014. 50 This analysis showed a 92% CR rate and a 6 month probability of sustained response of 76% (95% CI: 61-94%). The CR rate in the group of patients with >50% BM blasts just prior to T cell infusion was 82%. 3 of the patients in this group went on to SCT. These data suggest that T cells engineered to express a CD19-directed CAR have the potential to produce durable remissions, but more mature follow-up is needed across studies, as there are likely to be differences. Since much of our data to date is in pediatric patients, this could be one factor in the longer persistence our group has observed. However, more data from all groups testing highly proliferative gene-modified T cells will be needed before these differences can be better elucidated.
Toxicity
Cytokine Release Syndrome
The most common and potentially severe toxicity associated with CAR-modified T-cell therapy is cytokine release syndrome (CRS). [25] [26] [27] 42 Early data from our group and others suggest that there may be a correlation between development of CRS and response to therapy; patients who do not develop CRS may be less likely to benefit from CAR-modified T-cells, while those who develop CRS often respond to the therapy.
While there may be some correlation between developing CRS and efficacy, there does not appear to be a strong correlation between the degree of CRS and response to therapy. This is because of the confounding and strong impact of disease burden on the . Improved understanding of CRS may help determine which cytokines may be required for the therapy to be effective and which cytokines are not required and could be pharmacologically targeted to reduce inflammation and toxicity.
High levels of INF-γ or sIL2Ra would be expected after T-cell engaging therapies. In contrast, high levels of IL-6 or IL-10 would not be anticipated after CAR-modified T cells.
INF-γ is a proinflammatory cytokine produced by cytotoxic T cells, natural killer cells, and T-helper cells (T H 1)
. 54 INF-γ has a number of important functions including γ released by activated cytotoxic T cells after engagement may be important for the efficacy of CAR-modified T cells. Accordingly, while a number of INF-γ inhibitors are in clinical development, we would be hesitant to use them to ameliorate CRS. In children with genetic (primary) HLH, abnormally activated CD8 T cells secrete high levels of INF-γ, which in turn can stimulate uncontrolled macrophage activation and the CRS seen in primary HLH. 55 We hypothesize the INF-γ produced by the CAR-modified T cells may be driving the secondary MAS/HLH in patients with severe CRS.
Soluble (s)IL2Ra is released by a number of cell types, including cytotoxic T lymphocytes. 56 High levels of sIL2Ra are one of eight criteria used to diagnosis primary HLH, but high sIL2Ra levels are also found in patients with a large number of inflammatory disorders, autoimmune diseases, and malignancies. It is unknown whether targeting IL6 directly would be more effective at improving CRS than IL6R blockade. Based on the marked efficacy of tocilizumab in CRS post-CAR modified T cells, it is difficult to switch to an alternative therapy without compelling data.
We would, however, consider using siltuximab in a patient who does not respond to tocilizumab.
In addition to using cytokine-blocking drugs, our group and others have used given for 2-4 days at the peak of CRS.
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Thus far, the only reproducible predictor of severe CRS across clinical trials is high disease burden at infusion. 26 C-reactive protein (CRP) has been proposed as an indicator of severe CRS; 25 however, while high CRP correlates with severity of CRS in several studies, its use as a predictive biomarker is still being assessed. 26, 73 We are currently determining if cytokine levels may be better predictors of CRS severity. Our data suggest that peak levels of certain cytokines, including INF-γ and sIL2Ra are markedly more elevated in severe CRS than mild CRS. We need to identify biomarkers that can be easily measured soon after infusion that may predict which patients will become critically ill before they become sick. The window is short, as patients typically develop CRS within the first 5 days after infusion. We hypothesize that the pattern of a number of cytokines may be able to predict severity of CRS. As a number of clinical labs have developed CLIA-approved cytokine array testing, we anticipate in the future cytokine monitoring may be used to predict severity of CRS and to help guide management with cytokine blocking agents, including tocilizumab.
Encephalopathy
Neurologic toxicities have been reported after T cell engaging therapies, including distinct CAR-modified T cell therapies as well as blinatumomab. 25, 74, 75 Global encephalopathy is the most common toxicity, but seizures have also been reported. 25 In the CHOP/Penn experience with CTL019 in ALL patients, in addition to delirium at least partly attributable to high fever, 6/30 patients experienced a distinct encephalopathy syndrome that occurred after resolution of CRS. This encephalopathy is brief and selflimited, resolving over several days without intervention or apparent long-term sequelae. 
Challenges for CD19 CARs
CD19 CAR T cells have shown remarkable promise in ALL. Notwithstanding that success, challenges remain. For CAR T cell therapies to be available to more patients, the delivery of this therapy needs to be feasible across institutions. Expanding access will require comprehensive training of clinicians and a standardized approach to CRS grading and management. 67 Additional studies aimed at minimizing serious toxicities will be important as this therapy is exported to more sites. Across studies, disease burden appears to be correlated with CRS severity in responding patients. While disease burden is difficult to modify in a highly refractory population, prophylactic measures, develop and toxicity management evolves, the potential uses for this therapy will be expanded, as will access.
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